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BACKGROUND: Rhabdomyosarcoma (RMS) is the most common soft-tissue sarcoma in childhood with the ability to resist apoptosis
by the activation of survival promoting and anti-apoptotic proteins.
METHODS: Efficacy of the apoptosis-inducing agent betulinic acid (BA) was determined in RMS cell cultures and in vivo
by measuring cell viability, survival, apoptosis, hedgehog signalling activity, and neovascularisation.
RESULTS: Betulinic acid had a strong cytotoxic effect on RMS cells in a dose-dependent manner. The BA treatment caused a massive
induction of apoptosis mediated by the intrinsic mitochondrial pathway, which could be inhibited by the broad-range caspase
inhibitor zVAD.fmk. Exposure of hedgehog-activated RMS-13 cells to BA resulted in a strong decrease in GLI1, GLI2, PTCH1, and IGF2
expression as well as hedgehog-responsive luciferase activity. Intraperitoneal injection of 20mg BA per kg per day significantly
retarded growth of RMS-13 xenografts in association with markedly higher counts of apoptotic cells and down-regulation of GLI1
expression compared with control tumours, while leaving microvascular density, cell proliferation, and myogenic differentiation
unaffected.
CONCLUSION: Our data show that induction of apoptosis and inhibition of hedgehog signalling are important features of the anti-
tumourigenic effect of BA in RMS and advices this compound for the use in a multimodal therapy of this highly aggressive paediatric
tumour.
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Rhabdomyosarcoma (RMS) is the most common soft-tissue
sarcoma in children, representing B9% of paediatric solid cancers
(Crist and Kun, 1991). This tumour is thought to arise from
skeletal muscle precursor cells by interruption of normal myogenic
proliferation and differentiation processes, which are tightly
regulated through a variety of developmental genes, external
growth factors, and cell cycle-associated genes (Merlino and
Helman, 1999). Rhabdomyosarcoma is characterised by having
two major subtypes that differ in histology, degree of differentia-
tion, and prognosis: the embryonal form (ERMS) constituting
approximately two-thirds of all RMS and the rarer alveolar form
(ARMS) (Newton et al, 1995). Both subtypes are also distinguish-
able based on the detection of distinct molecular/genetic markers.
The ERMS is generally characterised by loss of heterozygosity
at the chromosomal band 11p15 (Visser et al, 1997), a region
harbouring the imprinted genes IGF2 and H19. In contrast, the
majority of ARMS are reported to have the characteristic
reciprocal translocations t(2;13)(p35;q14) and t(1;13)(p36;q14),
giving rise to PAX3– and PAX7–FKHR fusion proteins, respec-
tively (Shapiro et al, 1993; Davis et al, 1994). Currently, there is
data to suggest that ARMS are less sensitive to therapeutic
modalities than ERMS, with estimated 3-year event-free survival
rates of 66% and 83%, respectively (Crist et al, 2001). Furthermore,
high mortality rates remain in patients with metastatic disease
(Breneman et al, 2003). Failure of RMS treatment is commonly
considered on the basis of resistance of cancer cells to chemo-
therapeutic drugs. Recent studies, including those from our
laboratory, have shown that RMS characteristically display
activation of cell survival promoting and anti-apoptotic proteins
such as Akt and Bcl-2 (Kappler et al, 2003; Armistead et al, 2007).
This suggests that the resistance of RMS to chemotherapeutic
drugs might be associated with the inability of tumour cells
to undergo apoptosis. Therefore, an innovative therapeutic
approach using restoration of apoptotic defence might be effective
for the treatment of patients with this highly malignant tumour.
The naturally occurring pentacyclic triterpenoid betulinic acid
(BA) has been shown to possess anti-tumoural activity and
overcome resistance by inducing apoptosis in a variety of human
cancers (for review, see Alakurtti et al, 2006). Its selective cyto-
toxicity against cancer was first described on human melanoma
both in vitro and in vivo (Pisha et al, 1995). Since that initial study,
BA has been reported to be effective on a growing number of
human cancers, including those of the lung, colon, prostate, and
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sovary (Alakurtti et al, 2006), whereas normal cells were unaffected
by BA treatment (Zuco et al, 2002). Interestingly, BA has also been
successfully applied in vitro in childhood cancers, namely
medulloblastoma, glioblastoma, Ewing sarcoma (Fulda et al,
1999), neuroblastoma (Schmidt et al, 1997), and leukaemia
(Ehrhardt et al, 2004). Accumulated experimental evidence
indicates that BA causes distinct morphological changes in
sensitive cells, such as cell shrinkage, DNA fragmentation, nuclear
condensation, and membrane blebbing (Alakurtti et al, 2006).
The exact molecular mechanisms underlying BA-induced apopto-
sis are still not clear, but several studies suggest that the proteolytic
cleavage of caspases, the activation of the MAP kinase cascade,
the modulation of NF-kB signalling, the generation of reactive
oxygen species, and the inhibition of topoisomerase I may
have a function therein (for review, see Alakurtti et al, 2006). In
addition, BA has been shown to be effective on both drug-resistant
and drug-sensitive tumour cell lines, showing its significant
therapeutic benefit to chemotherapy-resistant cancer patients
(Sarek et al, 2003).
As BA suppresses tumour growth by inducing apoptosis, we
hypothesised that this phytochemical might promote cell death in
human RMS cells. In this study, we have investigated the time- and
dose-dependent growth inhibitory effects of BA in three RMS cell
lines and scrutinised whether BA treatment could lead to the
induction of apoptosis by the mitochondrial pathway. In addition,
we determined the impact of BA on hedgehog signalling, which has
been implicated in RMS development (Kappler et al, 2003; Tostar
et al, 2006). As in vivo data on BA treatment are scarce, we
furthermore analysed the in vivo effects triggered by BA in RMS-13
xenografts.
MATERIALS AND METHODS
Cell lines
The human RMS cell lines RH-30, RMS-13, and RD, as well as mouse
NIH-3T3 fibroblasts, were purchased from the German Collection of
Microorganisms and Cell Cultures (DSMZ, Braunschweig, Germany)
and the American Type Culture Collection (Manassas, VA, USA). All
cell lines were maintained as the suppliers recommended and tested
for authentication purposes for the expression of the myogenic
markers MyoD1, Myogenin, and Desmin (data not shown).
Cell viability and morphology
Cell growth was assessed using the Cell Proliferation Kit I
(Roche Diagnostics, Penzberg, Germany) according to the
manufacturer’s protocol. Cells were seeded at a density of
5 10
3 cells per 96-well plate (Nunc, Wiesbaden, Germany), and
after overnight attachment, cells were treated for 0–72h with
0–50mgml
–1 BA (BioSolutions, Halle, Germany) dissolved in
DMSO. Morphological changes of incubated cells were documen-
ted with a Zeiss-inverted phase-contrast microscope equipped with
a Canon PowerShot G6 digital device. Cell viability was measured
after addition of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazo-
lium bromide (MTT) labelling reagent on the GENios reader
(Tecan, Ma ¨nnedorf, Switzerland) at a wavelength of 595nm.
Clonogenic assay
Cells were seeded at a density of 2 10
3 cells per six-well plate.
After overnight attachment, cells were treated with 0–10mgml
–1
BA for 48h. After further 8 days growth without any treatment,
cells were fixed with methanol for 5min and stained with 0.5%
crystal violet. Clonogenic survival was determined by counting
stained colonies under a Zeiss-inverted phase-contrast microscope
and equipped with a Canon PowerShot G6 digital device.
Flow cytometric analysis
Cells were seeded at a density of 5 10
4 cells per 24-well plate.
After overnight attachment, cells were treated for 48h with
0–10mgml
–1 BA in the presence or absence of 50mM of the
broad-range caspase inhibitor zVAD.fmk (Bachem AG, Bubendorf,
Schweiz) dissolved in DMSO. Cells were trypsinised, washed in
PBS, and resuspended in 3.4mM sodium citrate per 0.1% Triton-X
100. Apoptotic cells were detected as a reduced sub-G1 peak
(fragmented DNA) after propidium iodide staining (1mgml
–1)
using an FACscan (Becton Dickinson, Heidelberg, Germany).
Western blot analysis
Cells were seeded at a density of 2 10
5 cells per six-well plate,
and after overnight attachment, cells were treated for 48h with
0–10mgml
–1 BA in the presence or absence of 50mM zVAD.fmk.
Cells treated with vehicle alone (DMSO) or 100mgml
–1 cyclo-
heximide (Sigma-Aldrich, Taufkirchen, Germany) were used as
negative and positive control, respectively. After treatment, cells
were scraped and lysed in PBS per 0.5% Triton-X 100 per 1mM
sodium-orthovanadate. Protein lysates were cleared of cellular
debris by centrifugation for 5min at 13000 r.p.m. at 41C. The
protein concentration was determined by the Protein Assay System
(Bio-Rad, Hercules, CA, USA). Equivalent amounts of proteins
were separated on 12% SDS–PAGE under reducing conditions and
then transferred to nitrocellulose membranes (GE Healthcare,
Piscataway, NJ, USA). The membranes were incubated with PBS
per 0.1% Tween 20 and 5% non-fat dry milk to block non-specific
binding. Membranes were incubated for 1.5h with mouse anti-
human caspase 3, rabbit anti-human cleaved caspase 3, rabbit anti-
human poly(ADP-ribose) polymerase (PARP), rabbit anti-human
b-actin (all from Cell Signalling Technology, Danvers, MA, USA),
mouse anti-human COX4, rabbit anti-human cytochrome c (both
from Clontech, Mountain View, CA, USA) or goat anti-human
GLI1 (C18; Santa Cruz Biotechnology, Santa Cruz, CA, USA)
antibodies, and thereafter for 1h with horseradish peroxidase-
conjugated goat anti-rabbit, goat anti-mouse, or rabbit anti-goat
IgG secondary antibodies (all from DakoCytomation, Hamburg,
Germany). Signals were visualised using the ECL chemilumines-
cence detection system (GE Healthcare).
Measurement of mitochondrial transmembrane potential
Cells were seeded at a density of 5 10
4 cells per 24-well plate.
After overnight attachment, cells were treated for 2–18h with
10mgml
–1 BA. Cells were then trypsinised, washed in PBS,
incubated for 15min with 40nM of the cationic lipophilic fluoro-
chrome 3,30-dihexyloxacarbocyanide iodide (DiOC6(3); Molecular
Probes, Eugene, OR, USA) at 371C and subsequently analysed by
flow cytometry using an FACscan (Becton Dickinson).
Real-time RT–PCR
Total RNA was extracted from tumour cell lines in Trizol
(Invitrogen, Carlsbad, CA, USA) according to the manufacturer’s
instructions. Reverse transcription of total RNA was performed
using random hexamers (Roche Diagnostics) and SuperScriptII
reverse transcriptase (Invitrogen). Real-time PCR and quantisation
of gene expression was performed as described earlier
(Eichenmuller et al, 2009a). For the human genes, we used the
following primer pairs (50-30 orientation): GLI1, AGCTACATCA
ACTCCGGCCA, GCTGCGGCGTTCAAGAGA; GLI2, TTCTCCAAC
GCCTCGGAC, GCCTGGGATCTTGCAGATGT; PTCH1,T T G A T T G
TGGGTGGCACAGT, GCTTGGGAGTCATTAACTGGAAC; IGF2,C C
TCCGACCGTGCTTCC, GGTGGACTGCTTCCAGGTGT; TBP,G C C C
GAAACGCCGAATAT, CCGTGGTTCGTGGCTCTCT. For the murine
genes, we used the following primer pairs: Shh, GGGAGCAGACC
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sGGCTGAT, CAGCTTCACTCCAGGCCACT; Gli1, GAATCGGACCC
ACTCCAATG, GTGTTTGCGGAGCGAGCT; Gli2, GTCACTGAAGG
ATTCCTGCTCG, CAGGACAGAACCATTGACTGGA; Ptch1,C T C C T
GAAACCCAAAGCCAA, CGTCTCTCACTCGGGTGGTC; Igf2,C G G A
GAGACTCTGTGCGGA, ACGGCTTGAAGGCCTGC; Tbp, TCACTC
CTGCCACACCAGC, TCAAGTTTACAGCCAAGATTCACG. Amplifi-
cation of the house-keeping gene TATA-Box-binding-Protein (TBP,
Tbp) was performed to standardise the amount of sample RNA.
Hedgehog reporter and activation assays
A total of 5 10
4 RMS-13 cells or NIH-3T3 fibroblasts were seeded
in 12-well plates the day before transfection. Tumour cells were
then transfected with 900ng of the reporter plasmid p11xGli or the
empty control pGL3-TK (Beer et al, 2003) and 100ng of the
reference plasmid pRL-TK using FuGene 6 transfection reagent
(Roche Diagnostics). Fibroblasts were accordingly transfected with
1mg of an expression plasmid containing the entire open reading
frame of the murine sonic hedgehog gene, which was kindly
supplied by Dr R Toftgard (Karolinska Institute, Stockholm,
Sweden). Twenty-four hours after transfection, cells were supple-
mented with 10mgml
–1 BA, 7.5mM cyclopamine (Toronto
Research Chemicals, Toronto, Canada), or vehicle as indicated
and cultured for 24h. For reporter assay, cells were lysed and
reporter gene activity was determined using the Dual-Glo
Luciferase Reporter Assay System (Promega, Madison, Wisconsin,
USA). Firefly luciferase activity was normalised to Renilla
luciferase activity. All reporter assay experiments were repeated
at least three times and transfections performed in duplicate.
For gene expression analysis, total RNA was isolated from
fibroblasts 24h after transfection using Trizol (Invitrogen).
Xenograft assay
Female NMRI nude mice (6–8 weeks old) were purchased from
Charles River (Sulzfeld, Germany) and housed in accordance with
the Institutional Animal Care guidelines. This study was approved
by the District Government of Upper Bavaria. Mice were divided
into two groups of five mice. Exponentially growing RMS-13 cells
were detached from culturing dishes by scraping and a 0.1-ml
suspension containing 2 10
7 cells was injected s.c. on the
right flanks above the hindlimb of each mouse. After 1 week, first
tumours were visible and palpable. After 10 days of tumour cell
injection, mice were treated intraperitoneally with a dose of 40mg
BA per kg body weight or vehicle every second day for a total
period of 16 days. The dose of BA was decided by referring to an
earlier report, which described a significant anti-tumour activity at
doses of 20mgkg
–1 per day and lack of toxicity at repeated doses
up to 500mgkg
–1 (Pisha et al, 1995). Tumour size was measured
every other day using calliper, and tumour volume was calculated
using the formula (X/2) (Y/2) (Z/2) (4/3 3.1415). Control
mice were injected with 0.1ml vehicle with a similar dosing
schedule. Body weights of the control and BA-treated mice were
recorded throughout the experiment. Mice were also monitored
for other symptoms of side effects including food and water
withdrawal and impaired posture or movement.
Immunohistochemistry
Tumour tissues from control and BA-treated mice were fixed in
4% neutral-buffered formalin, dehydrated, embedded in paraffin,
and sectioned at 4mm thickness. Cross-sections were deparaffi-
nised and rehydrated, and haematoxylin and eosin or Gomori’s
trichrome stained for histopathologic evaluation. For immuno-
histochemistry, endogenous peroxidase activity was quenched with
3% hydrogen peroxide in bi-distilled water. For antigen retrieval,
sections were either heated in a steamer in citrate buffer (pH6) for
40min or digested with protease XXIV (Sigma, Munich, Germany)
at 371C for 15min. Sections were then incubated overnight with
a polyclonal rabbit anti-cleaved caspase 3 (Cell Signalling
Technology), monoclonal mouse anti-Ki-67 (BD PharMingen,
San Diego, CA, USA), rat anti-mouse CD31 (Acris, Herford,
Germany), mouse anti-rat myogenin (DakoCytomation), or poly-
clonal rabbit anti-GLI1 (H-300; Santa Cruz Biotechnology) anti-
body all diluted 1:50 in PBS to assess apoptosis, cell proliferation,
microvessel density, myogenic differentiation, and hedgehog
signalling, respectively. Signal detection was achieved using the
Envision-Peroxidase system (DakoCytomation) with diaminoben-
zidine as chromogen. Tumour sections were counterstained with
haematoxylin. For the quantification of mean microvessel density,
total transverse sections were stained for CD31 and evaluated in
10 randomly selected fields at  400 magnification.
Statistical analysis
Data were expressed as means±s.d. and statistically subjected
to Student’s unpaired t-test. A level of Po0.05 was considered to
be significant.
RESULTS
BA treatment causes reduced cell viability and survival
of RMS cells
Owing to the remarkable success that BA displayed against many
forms of human cancer in vitro, we decided to investigate its
effects on RMS over time (0–72h) and selected a BA concentration
comparable with the one used in earlier reported studies
(Pisha et al, 1995; Fulda et al, 1997). As depicted in Figure 1A
(left panel), 10mgml
–1BA resulted in a 40% loss of viable cells in
RH-30 and RMS-13 cells already after 6h, as measured by MTT
assay. At the end of the time course (72h), viability of both cell
lines was o20% by this BA concentration. However, RD cells
display a certain adaptation to BA treatment over time. In a next
step, we determined the effect of different BA concentrations
(0–50mgml
–1) on RMS cells for a treatment period of 48h. We
observed that BA influences RMS-13 and RH-30 cells in a dose-
dependent manner, whereas RD cells were less responsive against
BA treatment (Figure 1A, right panel). However, high micromolar
concentrations (50mgml
–1) resulted in complete killing of all cell
lines. The half-maximal cytotoxic concentration (IC50) of BA was
5.0, 3.9, and 9.5mgml
–1for RMS-13, RH-30, and RD, respectively.
To scrutinise long-term effects of BA on RMS cells, clonogenic
assays were performed after adding varied concentrations of BA
(0–10mgml
–1). Loss of clonogenic survival of 90% and 65% was
shown at 10mgml
–1 BA in RMS-13 and RH-30 (Figure 1B),
respectively. In contrast, clonogenic survival of RD cells was hardly
reduced after BA treatment, indicating that these cells are less
responsive to BA.
BA induces apoptosis in RMS cells by affecting
mitochondria
As BA exerts its anti-tumourigenic effect by inducing apoptosis, we
next examined whether BA can induce morphological changes in
RMS. We found that BA treatment resulted in cell shrinkage,
membrane blebbing, and nuclear fragmentation of RMS-13 and
RH-30 cells (Figure 2A). In contrast, these apoptotic features were
not evident in RD cells. We next assessed BA-induced apoptosis by
flow cytometry of propidium iodide-stained nuclei (Figure 2B).
The DNA fragmentation was mainly detected in RMS-13 and to a
lower percentage in RH-30 and RD cells 48h after BA treatment.
However, in the presence of the broad-range caspase inhibitor
zVAD.fmk BA-induced apoptosis was significantly reduced in
RMS-13 cells, and to a lesser extent in RH-30 and RD cells
(Figure 2B), indicating that caspases were involved in BA-induced
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sapoptosis. We then selected the most responsive RMS cell line,
RMS-13, to see whether BA-induced apoptosis indeed requires
caspase activation. Therefore, we monitored the cleavage of
caspase 3 by western blot analysis 48h after BA treatment
(Figure 2C). Incubation of RMS-13 cells with BA led to cleavage
of caspase 3 and its known downstream target PARP. This effect
was partially blocked in the presence of zVAD.fmk, thus providing
evidence that the caspase-dependent pathway is involved in
BA-induced apoptosis.
As caspases act both in the extrinsic pathway (mediated by
death receptors) and the intrinsic pathway (mediated by death
signals inducing mitochondrial proteins), we wanted to know
which pathway is involved in BA-induced apoptosis of RMS.
Analysis of active caspase 8, which is a marker for the extrinsic
pathway, showed no changes after BA treatment (data not shown).
Conversely, by studying the effect of BA on mitochondrial
function, we found that incubation with BA results in an enhanced
breakdown of mitochondrial membrane potential in RMS-13 cells
(Figure 2D), reaching a maximum between 8 and 12h after BA
treatment. Next, we analysed whether this effect on mitochondria
could lead to the release of cytochrome c protein into the cytosol.
Our western blot analysis revealed increased cytochrome c levels in
the cytosol already 12h and more pronounced 24h after BA
treatment, whereas the cytochrome c concentration in the
mitochondrial fraction inversely decreased (Figure 2E). Together,
these results clearly indicate that BA-induced apoptosis in RMS-13
cells is mediated by the intrinsic apoptotic pathway.
BA specifically targets hedgehog signalling in RMS cells
Inappropriate hedgehog signalling has a fundamental function
in an increasing number of malignancies, including childhood
solid tumours such as medulloblastoma and RMS (Evangelista
et al, 2006). Interestingly, the most BA-responsive RMS cell line,
RMS-13, is known to display an activated hedgehog pathway
caused by a massive DNA amplification of the GLI1 locus (Roberts
et al, 1989). Thus, we wondered whether BA has any impact on this
signalling cascade. First, we verified that this genomic alteration
results in a strong expression of the GLI1 protein in RMS-13 cells
by western blot analysis (Figure 3A). Next, we analysed the
expression of the known hedgehog target genes GLI1, GLI2,
PTCH1, and IGF2 in RMS-13 cells after BA treatment. Strikingly,
we found a significant reduction of mRNA level for all four genes
in RMS-13 cells treated with BA (Figure 3B). This contrasts
the situation found in the two GLI1-negative RMS cell lines RH-30
and RD (Figure 3A), as transcription of these genes stayed
grossly unchanged (Figure 3B). Moreover, we found a significant
reduction in hedgehog activity of RMS-13 cells after BA treatment
by means of a hedgehog-responsive reporter assay (Figure 3C).
To examine whether this inhibition is dependent on hedgehog
signalling components upstream of GLI1, RMS-13 cells were
treated with BA in the presence or absence of 7.5mM cyclopamine,
a specific hedgehog signalling inhibitor (Taipale et al, 2000).
However, the inhibitory effect of BA on GLI1 activity was found to
be independent of cyclopamine treatment (Figure 3C), indicating
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Figure 1 (A) Decreased viability of RMS cells on BA treatment. The RMS cell lines were treated for 0–72h with 10mgml
–1(left panel) and for 48h with
0–50mgml
–1(right panel) BA. Cell viability was analysed by MTT assay in three independent experiments and is depicted as the mean percentage±s.d. of
viable cells. (B) BA inhibits clonogenic survival. The RMS cell lines were treated for 48h with 0–10mgml
–1BA. Representative experiments of untreated
(left) and 10mgml
–1BA-treated (right) cells are shown. Clonogenic survival was measured by counting crystal violet-stained colonies after 8 days. Mean and
s.d. of triplicates are shown; similar results were obtained in two independent experiments.
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sthat BA is able to selectively target hedgehog signalling on the
level of GLI1.
To further elucidate the concept of downstream hedgehog
pathway inhibition by BA under more physiological conditions, we
made use of untransformed NIH-3T3 fibroblasts, which have been
described to be responsible to sonic hedgehog (Taipale et al, 2000).
Activation of the pathway in NIH-3T3 cells by expressing the
ligand sonic hedgehog on transient transfection resulted in a
strong increase in expression of the known hedgehog target genes
Gli1, Gli2, Ptch1, and Igf2 (Figure 3D). As expected, the known
hedgehog inhibitor cyclopamine led to a significant reduction of
target gene expression in this activation assay. Strikingly, BA
treatment had an even stronger inhibitory effect on Gli1 and Gli2
expression, whereas Ptch1 and Igf2 stayed grossly unchanged.
Altogether, these findings indicate that BA is able to selectively
target hedgehog signalling directly on the level of GLI family
transcription factors.
Intraperitoneally administration of BA inhibits RMS-13
xenograft growth in athymic nude mice by selectively
inducing apoptosis
Next, we designed animal experiments to test whether BA
administration effectively inhibits growth of RMS-13 xenografts
and if BA causes programmed cell death in tumours in vivo.T o
reach this, we treated a group of mice (n¼5) with a palpable
tumour mass of B50mm
3 with 40mg BA per kg every second day
for a total of eight doses and compared their tumour growth with
a vehicle-treated control group (n¼5). As shown in Figure 4A,
BA treatment resulted in a dramatic reduction in tumour growth
compared with controls, as determined by measuring tumour
volume over time. However, tumour regression was not observed.
Furthermore, the lowered tumour growth was accompanied by
significantly decreased tumour weights in the treatment group
(Figure 4B). As it has been described that BA has anti-angiogenetic
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Figure 2 BA-induced apoptosis in RMS cell lines. (A) Morphology. The RMS cells were treated for 48h with or without 10mgml
–1 BA. Typical
morphological changes after apoptosis induction were observed in RMS-13 and RH-30 cells, but not in RD cells. Insets show apoptotic cells at high
magnification. (B) DNA fragmentation. The RMS cells were treated for 48h with 0–10mgml
–1BA in the presence or absence of 50mM of the broad-range
caspase inhibitor zVAD.fmk. Apoptosis-specific DNA fragmentation was determined by FACS analysis of propidium iodide-stained nuclei; 100mgml
–1
cycloheximide (CHX) was used as a positive control for apoptosis induction. Mean and s.d. from three independent experiments are shown; *Po0.05
(unpaired Student’s t-test). (C) Activation of apoptosis-specific proteins. The RMS-13 cells were treated for 48h with 0–10mgml
–1 BA in the absence
or presence of the broad-range caspase inhibitor zVAD.fmk. Expression of caspase 3, PARP, and b-actin was detected by western blot analysis. Cleaved
caspase 3 and PARP products are indicated by arrows; 100mgml
–1cycloheximide (CHX) was used as a positive control for apoptosis induction. (D) Loss of
mitochondrial membrane potential. The RMS-13 cells were treated for 0–18h with 10mgml
–1 BA. Mitochondrial membrane potential was measured by
flow cytometry using the potential-sensitive fluorochrome DiOC6(3). (E) Cytochrome c release. The RMS-13 cells were treated for 12 and 24h with
10mgml
–1BA. Mitochondria were isolated, lysed, and the expression of cytochrome c and COX4 in the mitochondrial and cytosolic fraction was detected
by western blot analysis.
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seffects on prostatic tumours in mice (Chintharlapalli et al, 2007),
we next evaluated blood microvessel density to see whether
lowered blood supply could be the reason for the growth
suppression of BA. In contrast to Chintharlapalli and co-workers,
our extensive morphometric analysis revealed no effects of BA
treatment on blood microvessel density (Figure 4C).
To investigate whether alteration in cell proliferation and/or
differentiation may have caused growth suppression of RMS-13
xenografts on BA treatment, we have stained for appropriate
markers by using immunohistochemistry. Unexpectedly, we found
no differences in the proportion of Ki-67 (Figure 5A) and
Myogenin-positive (Figure 5B) cells between BA- and vehicle-
treated tumours. However, histological examination of tumours of
the BA-treatment group revealed extensive tumour destruction as
evidenced by large areas of necrosis (Figure 5C). In line with this, we
detected a significant increase of apoptosis in BA-treated tumours
compared with the control group, as evidenced by staining for the
apoptotic marker cleaved caspase 3 (Figure 5D). Strikingly, BA
treatment led to a more regional expression of GLI1 leaving large
tumour areas unstained, as compared with the homogeneous GLI1
staining in untreated tumours. This suggests at least a partial down-
regulation of the hedgehog target on BA treatment. Altogether, these
findings indicate that BA is a potent inhibitor of RMS-13 growth in
vivo by selectively activating pro-apoptotic mechanisms and
inhibiting hedgehog signalling, without affecting the proliferative,
differentiating, and angiogenetic properties of this tumour.
DISCUSSION
Despite the development of multimodal therapies, the overall cure
rate of RMS remains low (Crist et al, 2001; Breneman et al, 2003).
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Figure 3 BA blocks hedgehog signalling (A) GLI1 expression of rhabdomyosarcoma cell lines. The RMS cell lines were lysed and the expression of GLI1
and b-actin was detected by western blot analysis. (B) Hedgehog signalling dependency. The RMS cells were treated for 48h with 10mgml
–1BA. GLI1, GLI2,
PTCH1, and IGF2 mRNA expression from untreated (black bars) and treated (grey bars) RMS cells was measured by quantitative real-time PCR in relation to
the house-keeping gene TBP as a calibrator; *Po0.05 (unpaired Student’s t-test). (C) Hedgehog pathway activity. The RMS-13 cells were transiently
transfected with 900ng hedgehog-responsive reporter plasmid (p11xGli) or control plasmid (pGL3-TK) and treated for 24h with 10mgml
–1 BA, 7.5mM
cyclopamine, 10mgml
–1 BA, and 7.5mM cyclopamine, or vehicle. Firefly luciferase activity was measured and normalised to the subsequently measured
Renilla luciferase activity. Reporter assay experiments were repeated three times and transfections performed in duplicate; *Po0.05 (unpaired Student’s
t-test). (D) Hedgehog activation assay. The NIH-3T3 cells were transiently transfected with 1mg sonic hedgehog (Shh) expression plasmid. For the inhibition
of hedgehog signalling, cells were additionally exposed to 10mgml
–1 BA and 7.5mM cyclopamine (Cycl.) 24h after transfection. Expression of the murine
genes Shh, Gli1, Gli2, Ptch1, and Igf2 was determined after an incubation period of 48h using quantitative real-time PCR in relation to the house-keeping gene
Tbp as a calibrator; *Po0.05 (unpaired Student’s t-test).
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sFailure of RMS treatment is commonly considered on the basis of
resistance of cancer cells to chemotherapeutic drugs. Thus, the
development and validation of new therapeutic approaches is of
utmost importance. This study revealed that BA administration
might be a promising strategy, as it not only inhibits growth of
human RMS cells by inducing apoptosis, but also blocks the
hedgehog signalling pathway.
There is accumulated experimental evidence indicating that
BA-induced apoptosis is not mediated by the extrinsic CD95 or
other death receptor/ligand systems, but acts directly on the
intrinsic mitochondrial pathway (Fulda et al, 1997, 1998). From
our data, it is safe to predict that BA induces apoptosis in RMS
cells too through the mitochondrial pathway, as evidenced by loss
of mitochondrial membrane potential, cytochrome c release from
mitochondria, increased levels of proteolytically cleaved caspase 3
and PARP, as well as absence of caspase 8 activation. Thus, by
directly initiating mitochondria-dependent apoptosis and thereby
acting on a more downstream level of apoptosis control BA
administration might be advantageous for treating tumours such
as RMS in which upstream components of apoptosis-inducing
signalling pathways are interrupted. One of these components, the
tumour suppressor protein p53, has been implicated in the cellular
response to stress such as DNA damage, hypoxia, and oncogene
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Figure 4 BA treatment suppressed RMS-13 xenograft growth. Female
NMRI nude mice carrying RMS-13 xenograft tumours were treated
intraperitoneally for 16 days with 20mg BA per kg body weight per day or
vehicle. (A) BA treatment induced a statistically significant decrease in
tumour growth as determined by volumetric measurement of BA-treated
(n¼5) and vehicle-treated (n¼5) mice. Error bars represent standard
error of the mean; *Po0.05 (unpaired Student’s t-test). (B) Mean tumour
weight and standard error of freshly dissected tumours of BA-treated and
vehicle-treated mice are shown; *Po0.05 (unpaired Student’s t-test).
(C) Mean microvascular density was determined by counting CD31-
immunostained vessels per mm
2 in RMS-13 xenografts of vehicle or
BA-treated mice. Error bars represent standard error of the mean.
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Figure 5 Induction of apoptosis and hedgehog inhibition in RMS in vivo.
Representative photographs of histological and immunohistochemical
stainings of untreated (left) and BA-treated (right) RMS-13 xenografts.
(A) Comparable amounts of cell proliferation in BA-treated and untreated
tumours as revealed by Ki-67 immunostaining. (B) Lack of induced
differentiation on BA treatment was revealed by immunostaining of the late
muscle marker myogenin. (C) Trichrome staining depicting extensive
tumour destruction (hemmed by a black line) in tumours of the treatment
group. (D) Cleaved caspase 3-immunopositive cells indicate a significant
higher apoptotic rate in BA-treated tumours compared with controls.
(E) Lack of GLI1 staining in large areas of BA-treated xenografts indicates
suppression of hedgehog signalling.
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sactivation and mediates either growth arrest or apoptosis
depending on cell type and particular conditions (Vousden and
Lu, 2002). However, as p53 wild-type (RMS-13; Muller et al, 2007)
and p53 mutant RMS cells (RH-30 and RD; Barlow et al, 2005)
were sensitive to BA treatment, it might be assumed that
BA-induced apoptosis in RMS cells is mediated by p53-independent
pathways. This is in line with an earlier study reporting lack of wild-
type p53 accumulation on BA treatment as well as association
between p53 mutation status and BA sensitivity in another
paediatric cancer, namely neuroblastoma (Fulda et al,1 9 9 7 ) .
Together, these data suggest that BA induces apoptosis in RMS
through the mitochondrial pathway in a p53-independent manner.
Angiogenesis is generally accepted as a prerequisite for tumour
growth beyond certain size as well as for metastatic spread and,
therefore, represents an attractive new target for tumour therapy
(Folkman, 2002). In recent years, anti-angiogenic treatments have
been shown to synergise with traditional chemotherapeutic and
radiotherapeutic regimens. Of note, BA has been described to have
not only a cytotoxic effect on endothelial cells, but also inhibits
tube-like structure formation of aortic endothelial cells (Kwon
et al, 2002; Mukherjee et al, 2004). However, using extensive
morphometric analyses, our study clearly shows that the growth-
inhibiting effect in RMS is solely based on the increase of apoptosis
in BA-treated tumours leaving CD31-positive microvessel density,
Ki-67-based proliferation index, and differentiation status
unaffected. This contrasts a recent study by Chintharlapalli et al
(2007) who reported on BA-induced anti-angiogenetic effects in
prostatic cancer cells grown as xenografts in nude mice. The
discrepancy in data concerning the anti-angiogenetic effect of BA
may be explained by the presence of alternative angiogenic factors
in RMS other than vascular endothelial growth factor (VEGF),
which has been described to be the primary target during
BA-induced anti-angiogenesis in LNCaP prostatic xenografts
(Chintharlapalli et al, 2007). The RMS are known to produce
basic fibroblast growth factor and interleukin-8 that stimulate their
growth and neovascularisation (Schweigerer et al, 1987; Pavlakovic
et al, 2001). Accordingly, Zhang et al (2002) showed that
monoclonal anti-VEGFR2 antibody treatment of RMS xenografts
led only to minor effects on tumour growth and angiogenesis, but
when combined with low-dose, doxorubicin results in full
responsiveness and complete remission. Contrarily, antibody-
mediated inhibition of VEGF in prostate cancer led to complete
suppression of angiogenesis and prevents tumour growth beyond
the initial prevascular growth phase (Borgstrom et al, 1998). Thus,
the redundancy of angiogenesis-sustaining factors in RMS could
be responsible for the high degree of vascularity found in our
treatment group after BA administration.
Another intriguing finding of our study is that BA impacts
on the hedgehog signal transduction pathway, which is known to
be aberrantly activated in a variety of human cancers, including
RMS (Kappler et al, 2003; Tostar et al, 2006). Overproduction
of hedgehog ligands, gain-of-function mutations in smoothened,o r
loss-of-function mutations in patched (PTCH1) and suppressor
of fused, all leading to constitutively activation of GLI family
transcription factors are the generally anticipated cause for
inappropriate hedgehog activation (reviewed in Evangelista et al,
2006). Thus, specific down-regulation of GLI family transcription
factors at the distal end of the signalling pathway might be
a desirable approach for bypassing the likely myriad of upstream
activating events. Our study now shows that BA is not only
effective on RMS-13 cells by decreasing cell viability and inducing
apoptosis, but also by effectively suppressing hedgehog target gene
expression. This is in line with our earlier finding that BA
suppresses hedgehog target genes in hepatoblastoma, another
embryonal tumour of early childhood (Eichenmuller et al, 2009b)
and a study by Rzeski et al (2006), which recently described that
BA decreases expression of BCL2, a gene, which is known to be
transcriptionally activated by GLI2 (Regl et al, 2004). As treatment
of GLI1-amplified RMS-13 cells with the hedgehog inhibitor
cyclopamine was unable to induce changes in reporter activity in
RMS-13 cells, these results suggest that BA inhibits hedgehog
signalling directly on the level of GLI family transcription factors.
This might be of enormous relevance, as a recent study reports on
high GLI1 expression levels in the majority of human RMS (Tostar
et al, 2006). However, the underlying molecular mechanism for
this activation is not entirely clear, as DNA amplifications at the
GLI1 locus has only been found in single RMS cases (Khatib et al,
1993; Goldstein et al, 2006) and PTCH1 mutations are relatively
rare in RMS (Calzada-Wack et al, 2002). Collectively, these data
suggest that BA-induced apoptosis could be at least in part
associated with the inhibitory effect of BA on hedgehog signalling
and its target genes.
Altogether, our study represents the first proof-of-principle
study of the effectiveness of BA on RMS-13 growth and hedgehog
signalling in vivo. However, it seems that accelerated cell survival
and activated hedgehog signalling are only part of the molecular
composition of RMS-13 cells, as no regression was observed in
BA-treated xenografts. Thus, other genetic lesions must be
responsible for driving the exacerbated proliferation, which stays
merely unchanged on BA treatment. It is highly probable that this
characteristic feature of RMS cells could be effectively tackled
by cytostatic drugs, thereby making combination therapies an
attractive option to treat this deadly cancer. Our finding on the
effective treatment of RMS-13 xenografts along with earlier in vivo
data on BA treatment of melanoma, ovarian carcinoma, and
prostate cancer (Pisha et al, 1995; Zuco et al, 2002; Chintharlapalli
et al, 2007) strongly encourages such efforts.
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